Robitussin and Imbruvica drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Robitussin and Imbruvica. Common interactions include exposure to communicable disease among females and pneumonia among males.

The phase IV clinical study analyzes what interactions people who take Robitussin and Imbruvica have. It is created by eHealthMe based on reports of 27 people who take Robitussin and Imbruvica from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Oct, 01, 2022

27 people who take Robitussin and Imbruvica together, and have interactions are studied.


What is Robitussin?

Robitussin has active ingredients of guaifenesin. eHealthMe is studying from 3,060 Robitussin users for its effectiveness, alternative drugs and more.

What is Imbruvica?

Imbruvica has active ingredients of ibrutinib. It is often used in chronic lymphocytic leukemia (cll). eHealthMe is studying from 50,132 Imbruvica users for its effectiveness, alternative drugs and more.

Number of Robitussin and Imbruvica reports submitted per year:

Robitussin and Imbruvica drug interactions.

Common Robitussin and Imbruvica drug interactions by gender *:

female:

  1. Exposure to communicable disease
  2. Headache
  3. Hypercapnia
  4. Lung disorder
  5. Lung infection
  6. Muscle spasms
  7. Pain in extremity
  8. Pneumonia
  9. Pneumonia pseudomonal
  10. Progressive multifocal leukoencephalopathy

male:

  1. Pneumonia
  2. Skin exfoliation
  3. Decreased appetite
  4. Dry mouth
  5. Eye disorder
  6. Eye pain
  7. Eye pruritus
  8. Eyelid irritation
  9. Eyelid margin crusting
  10. Insomnia

Common Robitussin and Imbruvica drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Acidosis
  2. Acute respiratory failure
  3. Hypercapnia
  4. Lung infection
  5. Pneumonia pseudomonal
  6. Pyrexia
  7. Sepsis
  8. Septic shock

50-59:

  1. Herpes zoster
  2. Nerve injury
  3. Supraventricular tachycardia

60+:

  1. Joint swelling
  2. Bone pain
  3. Death
  4. Aneurysm
  5. Ascites
  6. General physical health deterioration
  7. Injury
  8. Mastoid effusion
  9. Mucormycosis
  10. Anuria

Common conditions people have *:

  1. Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 16 people, 59.26%
  2. Lymphocytic Leukaemia (a type of cancer in which the bone marrow makes too many lymphocytes): 3 people, 11.11%
  3. Cough: 3 people, 11.11%
  4. Chronic Lymphocytic Leukaemia Recurrent (repeated cancer of blood cells known as lymphocytes): 2 people, 7.41%
  5. Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 2 people, 7.41%

* Approximation only. Some reports may have incomplete information.

Do you take Robitussin and Imbruvica?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Robitussin and Imbruvica:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Robitussin interactions:

Browse all interactions between Robitussin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Imbruvica interactions:

Browse all interactions between Imbruvica and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on guaifenesin and ibrutinib (the active ingredients of Robitussin and Imbruvica, respectively), and Robitussin and Imbruvica (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Robitussin and Imbruvica.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: